Skip to main content
Premium Trial:

Request an Annual Quote

UC Riverside Gets $600K NIH Grant to Support Big Data Research

NEW YORK (GenomeWeb) – The National Institutes of Health has awarded the University of California, Riverside $600,000 to support data-intensive research being conducted at the university, UCR announced on Thursday.

Specifically, the grant will go toward the purchase of a Big Data cluster with high-performance CPU resources and data storage space equal to about 5,000 laptops, UCR said, adding the grant would benefit more than 160 researchers from more than 15 departments and several colleges at the university.

In the grant's abstract contained in an NIH database, UCR researchers said that large-scale genomics and computational modeling approaches, such as next-generation sequencing and other high-throughput technologies, are routinely being used at the university in projects targeting neuroscience, cancer research, environmental health, wound healing, degenerative, and infectious diseases.

"Because these technologies output extremely large data sets, disk-based data storage required to process these 'Big Data' efficiently has become a major bottleneck to support the computational needs of NIH-funded biomedical research," the abstract said.

"With the new equipment grant from [the] NIH, [UCR's] compute facility will be able to at least quadruple its current compute resources, which should greatly help resolve our shortage of Big Data compute resources to support many new research programs," Thomas Girke, an associate professor of bioinformatics in the Department of Botany and Plant Sciences, and the principal investigator on the grant, said in a statement. Girke is also the director of UCR's central bioinformatics facility.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.